BioCryst presents new Orladeyo (berotralstat) results from APeX-P pediatric trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
BioCryst Pharmaceuticals announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) joint congress.
Included among these is a late-breaking abstract that highlights the first presentation of results from the APeX-P trial evaluating oral, once-daily Orladeyo in pediatric patients with HAE who are 2 to <12 years of age. The congress will take place in San Diego from 28 February – 3 March 2025.
BioCryst will present the following five abstracts on Sunday, 2 March from 9:45-10:45 am Pacific Time (PT) in Hall A at the San Diego Convention Center:
- HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P; Poster #L55
- Real-World Attack Rates Before and After Berotralstat Initiation Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency (Type I/II) Stratified by Monthly Baseline HAE Attack Frequency; Poster #603
- Real-World Attack Rates Before and After Berotralstat Initiation Among Patients with Hereditary Angioedema without C1-Inhibitor Deficiency (HAE-nl-C1-INH) Stratified by Monthly Baseline HAE Attack Frequency; Poster #607
- Exploring the Role of Disease Burden, Treatment Effectiveness, and Administration Preference on Willingness of Patients With HAE to Change Long-Term Prophylaxis; Poster #608
- Patient-Reported Impact of Berotralstat as Long-Term Prophylaxis on Hereditary Angioedema Attack Frequency and Attack Severity; Poster #655
(Source: BioCryst)